This site is intended for healthcare professionals

Alkermes plc announced the publication of phase III ENLIGHTEN-1 trial of ALKS 3831 in the Journal of Clinical Psychiatry .

Read time: 1 mins
Published:6th Mar 2020
Alkermes plc announced the publication of results from the phase III ENLIGHTEN-1 clinical trial of ALKS 3831 (olanzapine/samidorphan) in the peer-reviewed publication, Journal of Clinical Psychiatry . ENLIGHTEN-1 was a four-week study evaluating the efficacy, safety and tolerability of ALKS 3831 compared to placebo in 403 patients experiencing an acute exacerbation of schizophrenia. Positive topline data from the ENLIGHTEN-1 study were first reported in June 2017 . A New Drug Application (NDA) for ALKS 3831 is currently under FDA review, with a Prescription Drug User Fee Act (PDUFA) target action date of 15 November 2020 . ENLIGHTEN-1 is one of two key studies included in the ALKS 3831 ENLIGHTEN clinical development program. ENLIGHTEN-2, the second phase III study, assessed weight gain with ALKS 3831 compared to olanzapine over six months. Positive topline data from the ENLIGHTEN-2 study were reported in November 2018. See-"Efficacy and Safety of a Combination of Olanzapine and Samidorphan in Adult Patients With an Acute Exacerbation of Schizophrenia:Outcomes From the Randomized, Phase III ENLIGHTEN-1 Study"; Steven G. Potkin, MD; Jelena Kunovac, MD,; Bernard L. Silverman, MD; Adam Simmons, MPH; Ying Jiang, PhD; Lauren DiPetrillo, PhD; and David McDonnell, MD- Clin Psychiatry 2020;81(2):19m12769.
Condition: Schizophrenia + Bipolar Disorder
Type: drug

Learning Zones

The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.